BioSpace News Archive

Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it will host an investor presentation webcast on Thursday, January 28 at 2:00 p.m. EST ( 11:00 a.m. PST

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an agreement with Lentigen Technology, Inc. (“Lentigen”), a wholly-owned subsidiary of Miltenyi Biotec B.V. & Co. KG, to manufacture lentiviral vectors for Oncternal’s investigational ROR1-targeting CAR-T cell therapy program.

Centene Corporation issued a reminder that it will release its 2020 fourth quarter and full-year financial results at approximately 6 a.m. Eastern Standard Time on Tuesday, February 9th, 2021, and host a conference call afterwards at approximately 8:30 a.m. to review the results.

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started shipping its new synthetic RNA reference controls, which includes the new variant strain of SARS-CoV-2 identified in the United Kingdom. With this n

Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of Guardant Health’s proprietary blood tests to make a meaningful impact on patient care at the upcoming virtual 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium being held January 15-17, 2021. The presentations will co

Nonin Medical announced the appointment of four new members to the company’s board of directors. Each of the new directors brings unique industry experience and passion for innovation in the medtech and healthcare sectors.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today released a white paper detailing how the Versamune® platform works to treat cancer, and the potential of Versamune® in the treatment of a broad range of cancers.

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today reported financial and operating results for the first quarter of its fiscal year ended November 30, 2020 and provided a business update.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first enrollment in ADAPT-PD (Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson’s Disease (PD).

Angelini Pharma, an international pharmaceutical company which is a part of the private Italian Angelini Group – and Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today announced that they have concluded a definitive merger agreement under which Angelini Pharma will acquire Arvelle Therapeutics in an all cash transaction for a total aggregate valuation of up to $960 million.